ORIC
ORIC Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.74
+0.04%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -2.3%
- EBIT
- -4.3%
- EPS
- +28.6%
- Free cash flow
- +7.5%
- Operating cash flow
- +7.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -18.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -1.2%
- EBIT
- -0.1%
- Net income
- -1.3%
- EPS
- +19.7%
- Free cash flow
- -0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026